Weekly AtriCure, Inc. (NASDAQ:ATRC) Ratings on Jun 29, 2018

June 29, 2018 - By Mark Williams

AtriCure, Inc. (NASDAQ:ATRC) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 0.78. That’s change of 0.35, from 2017Q4’s 1.13. 10 investors sold all, 41 reduced holdings as AtriCure, Inc. ratio dived. 26 increased stakes while 14 funds acquired stakes. Funds hold 26.69 million shares thus 0.78% less from 2017Q4’s 26.90 million shares.
Swiss National Bank & Trust owns 56,900 shs. Trexquant Investment L P holds 0.02% or 10,913 shs. 6,208 were reported by Legal & General Gp Public Limited Company. Fmr Ltd Co stated it has 0.01% in AtriCure, Inc. (NASDAQ:ATRC). Vanguard Grp Inc Inc stated it has 1.51 million shs or 0% of all its holdings. Us Retail Bank De has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Wasatch Advsr invested 0.1% in AtriCure, Inc. (NASDAQ:ATRC). Weiss Multi holds 0.01% or 15,000 shs. Quantum Cap stated it has 108,887 shs or 0.54% of all its holdings. Barclays Public Lc invested in 0% or 21,438 shs. 11,294 are held by Metropolitan Life Insur New York. D E Shaw And accumulated 193,073 shs or 0.01% of the stock. Ontario – Canada-based Manufacturers Life Insur Com The has invested 0.01% in AtriCure, Inc. (NASDAQ:ATRC). Loomis Sayles Communication Ltd Partnership invested 0.04% of its capital in AtriCure, Inc. (NASDAQ:ATRC). The Georgia-based Voya Investment Management Limited Co has invested 0% in AtriCure, Inc. (NASDAQ:ATRC).

AtriCure, Inc. had 5 selling transactions and 2 insider buys since February 15, 2018. This’s net activity of $429,300. $228,200 worth of stock was sold by Krell Elizabeth D on Monday, May 7. On Thursday, March 1 GROVES REGINA E bought $17,430 worth of AtriCure, Inc. (NASDAQ:ATRC). On Thursday, June 14 a trade for 2,090 shs valued at $52,250 was made by Collar Mark A. On Thursday, March 1 Drake Scott William bought $194,040 worth of AtriCure, Inc. (NASDAQ:ATRC) or 11,000 shs.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Total analysts of 4 have positions in Atricure (NASDAQ:ATRC) as follows: 3 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 75%. Since January 8, 2018 according to StockzIntelligence Inc Atricure has 11 analyst reports. The stock rating was maintained by Needham with “Buy” on Tuesday, January 16. On Tuesday, February 27 Canaccord Genuity maintained AtriCure, Inc. (NASDAQ:ATRC) with “Buy” rating. On Friday, April 27 the firm has “Buy” rating by Needham given. On Monday, January 8 the firm has “Buy” rating by Canaccord Genuity given. On Monday, June 18 the firm has “Buy” rating by Needham given. On Wednesday, June 27 Canaccord Genuity maintained the shares of ATRC in report with “Buy” rating. On Friday, April 27 the stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Buy” rating by Stifel Nicolaus. On Wednesday, June 27 Needham maintained the shares of ATRC in report with “Buy” rating. On Tuesday, February 27 Needham maintained the shares of ATRC in report with “Buy” rating. On Wednesday, June 27 the firm has “Buy” rating by Stifel Nicolaus given. Listed here are AtriCure, Inc. (NASDAQ:ATRC) PTs and latest ratings.

27/06/2018 Broker: Canaccord Genuity Rating: Buy New Target: $35.0000 Maintain
27/06/2018 Broker: Needham Rating: Buy New Target: $32.0000 Maintain
27/06/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $23 New Target: $32 Maintain
18/06/2018 Broker: Needham Rating: Buy New Target: $32.0000 Maintain
27/04/2018 Broker: BTIG Research Rating: Hold
27/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $22 New Target: $23 Maintain
27/04/2018 Broker: Needham Rating: Buy New Target: $26.0000 Maintain
27/02/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain
27/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $26 Maintain
16/01/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain

Ticker’s shares touched $27.1 during the last trading session after 0.11% change.Currently AtriCure, Inc. is uptrending after 14.67% change in last June 29, 2017. ATRC has 34,783 shares volume. ATRC outperformed the S&P500 by 2.10%.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally.The firm is worth $949.58 million. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.Last it reported negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

For more AtriCure, Inc. (NASDAQ:ATRC) news published recently go to: Seekingalpha.com, Benzinga.com, Seekingalpha.com, Benzinga.com or Businesswire.com. The titles are as follows: “Market Is Revaluing Entertainment Stocks – Cramer’s Mad Money (6/14/18)” published on June 15, 2018, “25 Stocks Moving In Friday’s Pre-Market Session” on June 15, 2018, “Stocks To Watch: More Trade Tiffs And Stress Tests” with a publish date: June 23, 2018, “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” and the last “AtriCure Announces 2018 Analyst and Investor Meeting” with publication date: June 12, 2018.

AtriCure, Inc. (NASDAQ:ATRC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.